A drug prototype known as NZ-97 showed promise for treating pulmonary disease by stimulating growth of new stem cells to repair damaged tissue, based on data from a new proof-of-concept study.
The researchers identified dipeptidyl peptidase 4 inhibitors as potential tools to help promote production of stem cells in the lower airway called AEC2s. Dysfunction of AEC2 is thought to play a key role in the pathogenesis of idiopathic pulmonary fibrosis, the researchers noted in the study. They created a new and highly soluble DPP4 inhibitor known as NZ-97 that could be administered via intratracheal injection.
The current research"identifies a novel mechanism for promoting alveolar repair" and treating not only idiopathic pulmonary fibrosis but potentially other pulmonary diseases, such as
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Medscape - 🏆 386. / 55 Read more »
Source: PsychToday - 🏆 714. / 51 Read more »
Diabetes Drug Shows Promise Against Parkinson'sA drug used to treat diabetes slowed the progression of motor issues associated with Parkinson's disease, a study published in the New England Journal of Medicine said Wednesday.Parkinson's is a devastating nervous system disorder affecting 10 million people worldwide, with...
Source: NEWSMAX - 🏆 16. / 71 Read more »